Aurobindo Completes the Acquisition of Apotex’ Businesses in Poland, Czech Republic, the Netherlands, Spain and Belgium
Deepthi | Myequity news | Date : 11-02-2019 9:50:00 IST
Aurobindo Pharma Limited has closed the acquisition of Apotex’s commercial operations and certain supporting infrastructure in five European countries.
The binding agreement to acquire five of Apotex' European businesses, including infrastructure, personnel, products, certain established trademarks, marketing authorizations and dossier license rights in Poland, the Czech Republic, the Netherlands (including the manufacturing facility in Leiden), Spain and Belgium was announced on 14 July 2018.
Jefferies International Limited acted as sole financial advisor and Herbert Smith Freehills LLP acted as legal counsel to Aurobindo. Ernst & Young, India provided financial due diligence services.
Aurobindo Pharma Limited is a world-leading marketer and manufacturer of generic pharmaceuticals and active pharmaceutical ingredients. The company’s robust product portfolio is spread over 7 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, Anti-Allergies and Anti-Diabetics.